Prospective Grant of an Exclusive Patent License: Antibody-Based Therapy for the Treatment of CD20 Expressing Lymphomas, 31193 [2020-11036]
Download as PDF
<![CDATA[
31193
Federal Register / Vol. 85, No. 100 / Friday, May 22, 2020 / Notices
The National Heart, Lung, and
Blood Institute, an institute of the
National Institutes of Health,
Department of Health and Human
Services, is contemplating the grant of
an exclusive patent license to practice
the inventions embodied in the Patents
and Patent Applications listed in the
Supplementary Information section of
this notice to Retargeted Therapeutics, a
corporation incorporated under the laws
of the state of Delaware.
DATES: Only written comments and/or
applications for a license which are
SUMMARY:
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Prospective Grant of an Exclusive
Patent License: Antibody-Based
Therapy for the Treatment of CD20
Expressing Lymphomas
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
received by the National Heart, Lung,
and Blood on or before June 8, 2020 will
be considered.
Requests for copies of the
patent application, inquiries, and
comments relating to the contemplated
an exclusive patent license should be
directed to: Vidita Choudhry, Ph.D.
Technology Transfer Manager, 31 Center
Drive Room 4A29, MSC2479, Bethesda,
MD 20892–2479, phone number (301)–
594–4095, or vidita.choudhry@nih.gov.
ADDRESSES:
SUPPLEMENTARY INFORMATION:
INTELLECTUAL PROPERTY
NIH ref No.
E–758–2013–0–US–01 ..
E–758–2013–1–PCT–01
E–758–2013–1–US–02 ..
E–758–2013—1–CA–03
E–758–2013–1–EP–04 ..
E–758–2013–1–US–05 ..
E–025–2019–0–US–01 ..
Antibody Targeting Cell Surface Deposited
plement Protein C3d and Use Thereof.
Antibody Targeting Cell Surface Deposited
plement Protein C3d and Use Thereof.
Antibody Targeting Cell Surface Deposited
plement Protein C3d and Use Thereof.
Antibody Targeting Cell Surface Deposited
plement Protein C3d and Use Thereof.
Antibody Targeting Cell Surface Deposited
plement Protein C3d and Use Thereof.
Antibody Targeting Cell Surface Deposited
plement Protein C3d and Use Thereof.
Antibody Targeting Cell Surface Deposited
plement Protein C3d and Use Thereof.
Intellectual property listed here
includes all U.S. and foreign patents
and applications claiming priority to
any member of the aforementioned
applications.
The patent rights in these inventions
have been assigned or exclusively
licensed to the Government of the
United States of America.
The prospective exclusive license
territory may be worldwide and in fields
of use that may be limited to use of antiC3d monoclonal antibodies (mAbs) to
potentiate anti-tumor activity of antiCD20 mAbs for the treatment of B-cell
lymphomas.
The aforementioned Patents and
Patent applications cover technology
directed to development of anti-C3d
antibody or antibody fragments to retarget cells that have escaped from
existing mAbs therapy and to potentiate
the anti-tumor activity of therapeutic
mAbs and eliminate antigen loss
variants.
This notice is made in accordance
with 35 U.S.C. 209 and 37 CFR part 404.
The prospective exclusive license will
be royalty bearing. The prospective
exclusive license may be granted unless
within fifteen (15) days from the date of
this published notice, the National
Heart, Lung, and Blood Institute
receives written evidence and argument
that establishes that the grant of the
license would not be consistent with the
VerDate Sep<11>2014
Patent application
No.
Filing date
Issued patent
No.
Com-
61/924,967 ...............
January 8, 2014 ......
........................
Com-
PCT/US2015/010620
January 8, 2015 ......
........................
Com-
15/110,577 ...............
July 8, 2016 ............
10,035,848
Com-
2936346 ...................
January 8, 2015 ......
........................
Com-
15701442.4 ..............
January 8, 2015 ......
3092252
Com-
16/047,929 ...............
July 27, 2018 ..........
........................
Com-
62/945,569 ...............
December 9, 2019 ..
Title
18:07 May 21, 2020
Jkt 250001
requirements of 35 U.S.C. 209 and 37
CFR part 404.
In response to this Notice, the public
may file comments or objections.
Comments and objections, other than
those in the form of a license
application, will not be treated
confidentially, and may be made
publicly available.
License applications submitted in
response to this notice will be presumed
to contain business confidential
information and any release of
information in these license
applications will be made only as
required and upon a request under the
Freedom of Information Act, 5 U.S.C.
552.
Dated: May 14, 2020.
Bruce D. Goldstein,
Director, Office of Technology Transfer and
Development, National Heart, Lung, and
Blood Institute.
[FR Doc. 2020–11036 Filed 5–21–20; 8:45 am]
BILLING CODE 4140–01–P
PO 00000
Frm 00059
Fmt 4703
Sfmt 4703
Issue date
July 31, 2018.
September 18,
2019.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; NIAID Resource-Related
Research Projects (R24 Clinical Trial Not
Allowed).
Date: June 23, 2020.
Time: 1:30 p.m. to 3:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute of Allergy and
Infectious Diseases, National Institutes of
Health, 5601 Fishers Lane, Room 3F58,
E:\FR\FM\22MYN1.SGM
22MYN1
]]>Agencies
[Federal Register Volume 85, Number 100 (Friday, May 22, 2020)]
[Notices]
[Page 31193]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-11036]
[[Page 31193]]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Prospective Grant of an Exclusive Patent License: Antibody-Based
Therapy for the Treatment of CD20 Expressing Lymphomas
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The National Heart, Lung, and Blood Institute, an institute of
the National Institutes of Health, Department of Health and Human
Services, is contemplating the grant of an exclusive patent license to
practice the inventions embodied in the Patents and Patent Applications
listed in the Supplementary Information section of this notice to
Retargeted Therapeutics, a corporation incorporated under the laws of
the state of Delaware.
DATES: Only written comments and/or applications for a license which
are received by the National Heart, Lung, and Blood on or before June
8, 2020 will be considered.
ADDRESSES: Requests for copies of the patent application, inquiries,
and comments relating to the contemplated an exclusive patent license
should be directed to: Vidita Choudhry, Ph.D. Technology Transfer
Manager, 31 Center Drive Room 4A29, MSC2479, Bethesda, MD 20892-2479,
phone number (301)-594-4095, or [email protected].
SUPPLEMENTARY INFORMATION:
Intellectual Property
--------------------------------------------------------------------------------------------------------------------------------------------------------
Issued patent
NIH ref No. Title Patent application No. Filing date No. Issue date
--------------------------------------------------------------------------------------------------------------------------------------------------------
E-758-2013-0-US-01............... Antibody Targeting 61/924,967................ January 8, 2014.......... .............. .........................
Cell Surface
Deposited
Complement Protein
C3d and Use
Thereof.
E-758-2013-1-PCT-01.............. Antibody Targeting PCT/US2015/010620......... January 8, 2015.......... .............. .........................
Cell Surface
Deposited
Complement Protein
C3d and Use
Thereof.
E-758-2013-1-US-02............... Antibody Targeting 15/110,577................ July 8, 2016............. 10,035,848 July 31, 2018.
Cell Surface
Deposited
Complement Protein
C3d and Use
Thereof.
E-758-2013--1-CA-03.............. Antibody Targeting 2936346................... January 8, 2015.......... ..............
Cell Surface
Deposited
Complement Protein
C3d and Use
Thereof.
E-758-2013-1-EP-04............... Antibody Targeting 15701442.4................ January 8, 2015.......... 3092252 September 18, 2019.
Cell Surface
Deposited
Complement Protein
C3d and Use
Thereof.
E-758-2013-1-US-05............... Antibody Targeting 16/047,929................ July 27, 2018............ ..............
Cell Surface
Deposited
Complement Protein
C3d and Use
Thereof.
E-025-2019-0-US-01............... Antibody Targeting 62/945,569................ December 9, 2019......... .............. .........................
Cell Surface
Deposited
Complement Protein
C3d and Use
Thereof.
--------------------------------------------------------------------------------------------------------------------------------------------------------
Intellectual property listed here includes all U.S. and foreign
patents and applications claiming priority to any member of the
aforementioned applications.
The patent rights in these inventions have been assigned or
exclusively licensed to the Government of the United States of America.
The prospective exclusive license territory may be worldwide and in
fields of use that may be limited to use of anti-C3d monoclonal
antibodies (mAbs) to potentiate anti-tumor activity of anti-CD20 mAbs
for the treatment of B-cell lymphomas.
The aforementioned Patents and Patent applications cover technology
directed to development of anti-C3d antibody or antibody fragments to
re-target cells that have escaped from existing mAbs therapy and to
potentiate the anti-tumor activity of therapeutic mAbs and eliminate
antigen loss variants.
This notice is made in accordance with 35 U.S.C. 209 and 37 CFR
part 404. The prospective exclusive license will be royalty bearing.
The prospective exclusive license may be granted unless within fifteen
(15) days from the date of this published notice, the National Heart,
Lung, and Blood Institute receives written evidence and argument that
establishes that the grant of the license would not be consistent with
the requirements of 35 U.S.C. 209 and 37 CFR part 404.
In response to this Notice, the public may file comments or
objections. Comments and objections, other than those in the form of a
license application, will not be treated confidentially, and may be
made publicly available.
License applications submitted in response to this notice will be
presumed to contain business confidential information and any release
of information in these license applications will be made only as
required and upon a request under the Freedom of Information Act, 5
U.S.C. 552.
Dated: May 14, 2020.
Bruce D. Goldstein,
Director, Office of Technology Transfer and Development, National
Heart, Lung, and Blood Institute.
[FR Doc. 2020-11036 Filed 5-21-20; 8:45 am]
BILLING CODE 4140-01-P
